PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The Company's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle.

Employees

Sector

Biotechnology & Medical Research

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets Other stock markets 13:31:34 2025-12-10 EST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-

19-01-30	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
18-03-23	PhaseRx, Inc. Bankruptcy Case Dismissed	CI

Market Cap	4.56M 4.01M 3.73M 3.43M 6.43M 442M 6.54M 44.54M 17.37M 215M 17.12M 16.75M 747M	P/E 2015 *	-	P/E 2016	-0.58x
Enterprise Value	-5.22M -4.59M -4.26M -3.92M -7.35M -505M -7.48M -50.97M -19.88M -246M -19.58M -19.16M -855M	EV / Sales 2015 *	-	EV / Sales 2016	-
Free-Float	100%	Yield 2015 *	-	Yield 2016	-

19-01-30	Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc.	CI
18-03-23	PhaseRx, Inc. Bankruptcy Case Dismissed	CI
18-03-06	Motion for Case Dismissal Filed for PhaseRx, Inc.	CI
18-02-20	Motion for De Minimis Asset Sale Approved for PhaseRx, Inc.	CI
18-02-02	PhaseRx, Inc.(OTCPK:PZRX.Q) dropped from NASDAQ Composite Index	CI
18-02-01	Motion for Asset Sale Approved for PhaseRx, Inc.	CI
18-01-31	Roivant Sciences GmbH entered into an asset purchase agreement to acquire substantially all of the assets from PhaseRx, Inc. for $6.8 million.	CI
17-12-27	Bidding Procedure Approved for PhaseRx, Inc.	CI
17-12-14	PhaseRx Considers Multiple Alternatives	CI
17-12-13	PhaseRx, Inc.(NasdaqCM:PZRX) dropped from S&P TMI Index	CI
17-12-11	PhaseRx, Inc. Filed for Bankruptcy	CI
17-12-11	Motion for Asset Sale Filed by PhaseRx, Inc.	CI
17-11-09	PhaseRx, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	CI

1 year	0		0
3 years	0		0
5 years	0		0.03
10 years	0		3.98

PhaseRx, Inc. Stock

Stocks

PZRXQ

US71723F1030

Biotechnology & Medical Research

Valuation: PhaseRx, Inc.

Chart: PhaseRx, Inc.

Latest news : PhaseRx, Inc.

Course Extremes

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHASERX, INC.	-.--%	-.--%	-	-	11
WUXI APPTEC CO., LTD.	+1.23%	-3.08%	+53.96%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+66.42%	54.15B
INSMED INCORPORATED	+0.52%	-0.56%	+3.31%	+422.29%	23.11B
BIONTECH SE	+0.34%	+0.43%	-19.76%	-14.08%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	+1.03%	-0.76%	+40.14%	-3.59%	20.33B
GENMAB A/S	-0.37%	+0.71%	+31.36%	-29.32%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.87%	-2.80%	+37.96%	+600.00%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-12.88%	+168.62%	+289.45%	15B
EXELIXIS, INC.	+1.15%	-0.07%	+22.56%	+179.74%	13.82B
Average	+0.74%	-0.33%	+44.59%	+177.65%	23.86B
Weighted average by Cap.	+1.55%	+1.19%	+45.42%	+140.74%

	2015	2016
Net sales	375K 330K 306K 282K 528K 36.32M 538K 3.66M 1.43M 17.71M 1.41M 1.38M 61.45M	-
Net income	-7.38M -6.49M -6.03M -5.54M -10.4M -714M -10.58M -72.08M -28.11M -348M -27.69M -27.1M -1.21B	-20.14M -17.71M -16.45M -15.13M -28.38M -1.95B -28.89M -197M -76.74M -951M -75.6M -73.96M -3.3B
Net Debt	16.55M 14.56M 13.52M 12.44M 23.32M 1.6B 23.74M 162M 63.07M 782M 62.14M 60.79M 2.71B	-9.78M -8.6M -7.99M -7.35M -13.78M -947M -14.02M -95.51M -37.26M -462M -36.7M -35.91M -1.6B